Capsida Biotherapeutics names new chief scientific officer
8 March 2023 -

Capsida Biotherapeutics Inc., a US-based fully integrated next-generation gene therapy platform company, announced on Tuesday that it has named Susan Catalano, PhD as its new chief scientific officer (CSO).

In the new role, Dr Catalano is to continue to build on the company's foundation of excellence in next-generation gene therapy science along with co-founders Nicholas Flytzanis, PhD and Nick Goeden, PhD, to advance the firm's pipeline into the clinic.

Dr Catalano has over two decades of experience heading discovery, translational science and clinical functions to bring multiple therapies in neurological and oncology indications to the clinic. She has served in various roles including CSO of CODA Biotherapeutics, a member of the board of directors of Cognition Therapeutics, CSO and co-founder of the company, scientific leadership positions at Acumen Pharmaceuticals, Rigel Pharmaceuticals, and Roche Palo Alto.

Currently, Dr Catalano serves on the External Advisory Board for various National Institutes of Health (NIH) clinical initiatives, various NIH review panels in the areas of drug discovery and clinical development for neurodegenerative diseases and peer-reviewed scientific journal editorial boards.